ChemPartner PharmaTech Co Ltd

Ruizhi Pharma disclosed its 2026 semi-annual report on August 29. In the first half of the year, total operating revenue reached 562 million yuan, up 5.37% year on year, but net profit attributable to the parent company showed a loss of 30.99 million yuan, compared with a profit of 25.38 million yuan in the same period last year. Net profit after deducting non-recurring items was a loss of 31.95 million yuan, compared with a profit of 6.79 million yuan a year earlier. Net cash flow from operating activities was 39.97 million yuan, down 38.82% year on year. Basic earnings per share were negative 0.0622 yuan, and the weighted average return on equity was negative 2.43%. The company's main businesses include pharmaceutical R&D services and contract manufacturing outsourcing, as well as health and medical services.